Pharmaceutical Microbiology and Biotechnology

Contamination control, product sterility, and biological consistency are non-negotiables for modern medicines. Pharmaceutical Microbiology & Biotechnology brings together microbiologists, bioprocess engineers, QC leaders, and regulators to build reliable systems from cell bank to finished product. This session examines the science and operations that protect patient safety while enabling efficient manufacturing across vaccines, monoclonal antibodies, RNA therapeutics, and advanced therapy medicinal products. Attendees will explore environmental monitoring strategies that truly reflect risk, practical approaches to contamination control strategy (CCS), and modern sterility assurance for aseptic processing and terminal sterilization. The program compares culture-based methods with rapid microbiological methods, clarifying when ATP bioluminescence, flow cytometry, or qPCR/NGS add actionable speed without compromising specificity.

Biotechnology topics emphasize upstream intensification, downstream recovery, and impurity control that preserves product quality attributes. Case studies illustrate how media design, feed strategies, and single-use technologies influence bioburden, endotoxin, and adventitious agent risk. We address endotoxin challenges—including low endotoxin recovery—and the appropriate use of the monocyte activation test to complement or replace rabbit pyrogen testing. For cell and gene therapy, the session delves into viral safety evaluations, mycoplasma testing 2.0, and chain-of-identity documentation that links analytics to batch release.

Analytics and compliance are woven throughout: validation of rapid micro methods, data integrity for trend analysis, and alignment with evolving regulations and Annex 1 expectations. We connect microbiology to real manufacturing decisions—how facility zoning, airflow visualization, and operator qualification reduce interventions and how cleaning, disinfection rotation, and sporicidal practices sustain control over time. For professionals seeking a Pharmaceutical Science Conference, the track delivers a practical roadmap to link monitoring signals with root-cause investigations and CAPA that actually prevents recurrence. The importance of sterility assurance is reinforced with examples that translate CCS into day-to-day behaviors, not just documents.

Finally, the session explores microbiome-based therapeutics and engineered probiotics, highlighting identity, potency, and viability challenges unique to live biotherapeutic products. Whether you work in QC labs, manufacturing science, or process development, you’ll leave with frameworks that improve detection sensitivity, shorten release timelines, and strengthen the microbial control culture across your organization.